Show simple item record

dc.contributor.authorElkoumy, Ahmed
dc.contributor.authorJose, John
dc.contributor.authorTerkelsen, Christian J
dc.contributor.authorNissen, Henrik
dc.contributor.authorGunasekaran, Sengottuvelu
dc.contributor.authorAbdelshafy, Mahmoud
dc.contributor.authorSeth, Ashok
dc.contributor.authorElzomor, Hesham
dc.contributor.authorKumar, Sreenivas
dc.contributor.authorBedogni, Francesco
dc.contributor.authorIelasi, Alfonso
dc.contributor.authorDora, Santosh K
dc.contributor.authorChandra, Sharad
dc.contributor.authorParikh, Keyur
dc.contributor.authorUnic, Daniel
dc.contributor.authorWijns, William
dc.contributor.authorBaumbach, Andreas
dc.contributor.authorMylotte, Darren
dc.contributor.authorSerruys, Patrick
dc.contributor.authorSoliman, Osama
dc.date.accessioned2024-09-10T13:26:42Z
dc.date.available2024-09-10T13:26:42Z
dc.date.issued2022-01-15
dc.identifier.issn2077-0383
dc.identifier.pmid35054137
dc.identifier.doi10.3390/jcm11020443
dc.identifier.urihttp://hdl.handle.net/10147/642831
dc.descriptionBicuspid aortic valve (BAV) is the most common valvular congenital anomaly and is apparent in nearly 50% of candidates for AV replacement. While transcatheter aortic valve implantation (TAVI) is a recommended treatment for patients with symptomatic severe aortic stenosis (AS) at all surgical risk levels, experience with TAVI in severe bicuspid AS is limited. TAVI in BAV is still a challenge due to its association with multiple and complex anatomical considerations. A retrospective study has been conducted to investigate TAVI's procedural and 30-day outcomes using the Myval transcatheter heart valve (THV) (Meril Life Sciences Pvt. Ltd. Vapi, Gujarat, India) in patients with severe bicuspid AS. Data were collected on 68 patients with severe bicuspid AS who underwent TAVI with the Myval THV. Baseline characteristics, procedural, 30-day echocardiographic and clinical outcomes were collected. The mean age and STS PROM score were 72.6 ± 9.4 and 3.54 ± 2.1. Procedures were performed via the transfemoral route in 98.5%. Major vascular complications (1.5%) and life-threatening bleeding (1.5%) occurred infrequently. No patient had coronary obstruction, second valve implantation or conversion to surgery. On 30-day echocardiography, the mean transvalvular gradient and effective orifice area were 9.8 ± 4.5 mmHg and 1.8 ± 0.4 cm2, respectively. None/trace aortic regurgitation occurred in 76.5%, mild AR in 20.5% and moderate AR in 3%. The permanent pacemaker implantation rate was 8.5% and 30-day all-cause death occurred in 3.0% of cases. TAVI with the Myval THV in selected BAV anatomy is associated with favorable short-term hemodynamic and clinical outcomes.en_US
dc.language.isoenen_US
dc.rightsAttribution 4.0 International*
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/*
dc.subjectaortic stenosisen_US
dc.subjectbicuspid aortic valveen_US
dc.subjectTranscatheter aortic valve implantationen_US
dc.titleSafety and Efficacy of Myval Implantation in Patients with Severe Bicuspid Aortic Valve Stenosis-A Multicenter Real-World Experience.en_US
dc.typeArticleen_US
dc.identifier.journalJournal of clinical medicineen_US
dc.source.journaltitleJournal of clinical medicine
dc.source.volume11
dc.source.issue2
refterms.dateFOA2024-09-10T13:26:44Z
dc.source.countrySwitzerland


Files in this item

Thumbnail
Name:
jcm-11-00443.pdf
Size:
1.028Mb
Format:
PDF

This item appears in the following Collection(s)

Show simple item record

Attribution 4.0 International
Except where otherwise noted, this item's license is described as Attribution 4.0 International